LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
08/11/2026
Back to search
Official data from USPTO
T ACELLT APEIRON CELL THERAPIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
08/11/2026
Trademark type
Combined
Nice classes
1, 5, 42
Filing date
08/03/2020
Registration date
07/26/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/26/2022
Last transaction
08/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
98
Owner location
AT
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "ACELLT" with the "A" in blue font, the "T" in orange font, and the remaining letters in gray font. Below this is the wording "APEIRON CELL THERAPIES" in gray font. To the left of all the wording is stylized infinity symbol with the left portion of the symbol in blue, the middle of the symbol is an orange stylized "T" and the right portion of the symbol is gray. The white in the mark is background only and is not claimed as a feature of the mark.
Holders and representatives
Holders
APEIRON Biologics GmbH
APEIRON BIOLOGICS AG
Representatives
Julianne Abelman Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicalbiochemical and biotechnological preparations for industrial and scientific purposes
Class 5
Pharmaceutical and veterinary preparationspharmaceutical preparations for treating and preventing cancerpharmaceutical preparations for cellular therapy; diagnostic preparations for medical purposes; sanitary preparations for medical purposes
Class 42
Scientific and technological services and research and design relating theretoin particular analysis services in the field of researchdevelopment and diagnosticsscientific researchmedical research for medical applicationsdevelopment of new products for others; industrial analysis and research services in the field of cancer treatmentcell processingcellular therapy
Publications
History of USPTO decisions and trademark events.
44 publications found
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
05/09/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
01/16/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/04/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/20/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/28/2022
FIMP
FINAL DISPOSITION PROCESSED
10/27/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/26/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/26/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
07/26/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/20/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/20/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/20/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/20/2022
GPNX
NOTIFICATION PROCESSED BY IB
05/15/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/10/2022
PUBO
PUBLISHED FOR OPPOSITION
05/10/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/20/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/20/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/20/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/04/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
04/04/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/04/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
04/04/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/04/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/21/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/02/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/02/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/26/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/23/2021
GNFR
FINAL REFUSAL E-MAILED
06/23/2021
CNFR
FINAL REFUSAL WRITTEN
06/23/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/20/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/19/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/19/2021
RFNT
REFUSAL PROCESSED BY IB
12/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/09/2020
RFRR
REFUSAL PROCESSED BY MPU
12/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/01/2020
CNRT
NON-FINAL ACTION WRITTEN
11/30/2020
DOCK
ASSIGNED TO EXAMINER
11/24/2020
MAFR
APPLICATION FILING RECEIPT MAILED
10/09/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/01/2020
Continuous trademark protection
Get notified about every new filing that threatens T ACELLT APEIRON CELL THERAPIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.